SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michail Shadkin who wrote (5590)9/10/2001 1:28:51 PM
From: Art Baeckel  Read Replies (1) of 6873
 
Do you have a target for LCBM Michail? It really jumped on the news! Thanks, ART

Lifecore stock jumps after gel ruling

By Ted Griffith, CBS.MarketWatch.com
Last Update: 4:55 PM ET Sept. 7, 2001

CHASKA, Minn. (CBS.MW) -- Shares of Lifecore Biomedical soared more
than 50 percent Friday after mediators found that the Food and Drug
Administration had wrongly rejected the medical device maker's gel
designed to reduce scarring from surgery.

Shares of Lifecore (LCBM: news, chart, profile) moved up $3.14 to $9.04.

The Chaska, Minn.-based company announced
Thursday that an FDA dispute resolution panel, made
up of medical experts, had ruled in the company's
favor and said Lifecore's gel should be approved.

The decision was the first of its kind under a system
established to mediate disputes between the federal
agency and medical device companies. It's now up to
the director of the FDA's devices unit as to whether to
approve the product, known as Gynecare Intergel.

Analyst Thomas Gunderson at US Bancorp Piper
Jaffray, saying that final approval now appears to be
just a formality, predicted the gel will be cleared for
marketing within three months. The analyst upgraded
his rating on Lifecore's stock from "neutral" to "strong
buy."

Gunderson said Lifecore Biomedical already has
products on the market, including dental implants, but
the anti-scarring gel appears to have the most
commercial potential.

"This product is the home-run hitter," Gunderson said.

Gunderson expects the gel initially will be used in
gynecological surgeries and estimated the ultimate
potential market could be as high as $500 million.

If it does win final clearance, the gel will be marketed
by health-care giant Johnson & Johnson (JNJ: news,
chart, profile). After a recent run to higher ground,
shares of J&J fell $1.21 to $55.73.

Gunderson said the action of the mediators could
also have positive implications for the whole medical device sector. He said the
dispute resolution process offers companies another opportunity to win approval
for their products.

"The industry lobbied for this, they got it, and now they're seeing that it works,"
Gunderson said.

Ted Griffith is a reporter for CBS.MarketWatch.com

More SCREAMERS
•Community Savings surges on acquistion news 12:20pm ET 09/10/01
•Gap shares plunge to a near four-year low 4:06pm ET 09/06/01
•Portugal Telecom offer withdrawl sinks Telesp Celular 5:49pm ET 09/05/01
•Novoste's stock tumbles after rival J&J's success 5:07pm ET 09/04/01
•Loudcloud shares soar after better-than-expected result 10:22am ET 08/30/01
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext